Levetiracetam in the treatment of epilepsy in adults. Experience with monotherapy;Levetiracetam en el tratamiento de la epilepsia del adulto. Experiencia en monoterapia

Revista de Neurologia

Volumn 45, Issue 6, 2007, Pages 331-333

  Molins, Albert ^a   Villanueva, V E ^b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Effectiveness; Epilepsy; Levetiracetam; Monotherapy; Retrospective; Safety

Indexed keywords

ETIRACETAM;

ADULT; AGED; ANOREXIA; ARTICLE; CHILL; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; EPILEPSY; FATIGUE; FOLLOW UP; HUMAN; IRRITABILITY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; SOMNOLENCE;

EID: 37349026203     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4506.2007198     Document Type: Article

References (16)

1. Alsaadi TM, Thieman C, Zusman E. Levetiracetam monotherapy for adults with localization-related epilepsy. Epilepsy Behav 2002; 3: 471-4.
2. Alsaadi TM, Shatzel A, Márquez AV, Jorgensen J, Farias S. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure 2005; 14: 139-42.
3. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-released carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-8.
4. Agencia Europea del Medicamento (EMEA). Ficha técnica del levetiracetam. URL: http://www.emea.eu.int/humandocs/PDFs/EPAR/keppra/H-277-PI- es.pdf. [30.04.2007].
5. Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualized doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Seizure 2003; 12: 141-9.
6. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707-24.
7. Armijo JA, Sánchez MB, Campos C, Adín J. Interacciones de los antiepilépticos en la práctica oncológica. Rev Neurol 2006; 42: 681-90.
8. Poza-Aldea JJ. Epilepsia en ancianos. Rev Neurol 2006; 42: 42-6.
9. Bazil CW, Rose A, Resor S, Yapicular B, Hirsch LJ. Levetiracetam may be more effective for late-onset partial epilepsy. Arch Neurol 2002; 59: 1905-8.
10. Ferrendelli JA, French J, Leppik I, Morrell MJ, Herbeuval A, Han J, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003; 4: 702-9.
11. White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak TE, et al. Discontinuation of levetiracetam because of behavioural side effects. A case control study. Neurology 2003; 61: 1218-21.
12. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61: 704-6.
13. Mohanraj R, Parker PG, Stephen LJ, Brodie MJ. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 2005; 14: 23-7.
14. Morrell MJ, Leppik I, French J, Ferrendelli J, Han J, Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54: 153-61.
15. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord 2003; 5: 125-32.
16. Villanueva V, Gómez-Caigoya A, Gutiérrez-Delicado E, Serratosa JM. Estudio abierto, prospectivo y observacional de eficacia y tolerabilidad con levetiracetam durante un año de seguimiento. Neurologia 2007; 22: 348-53.